X4 Pharmaceuticals Announces Industry Veteran Dr. Christophe Arbet-Engels to Join as Chief Medical Officer
August 08, 2023 16:05 ET
|
X4 Pharmaceuticals
BOSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of...
X4 Pharmaceuticals Closes $115 Million Loan Facility with Hercules Capital
August 03, 2023 08:00 ET
|
X4 Pharmaceuticals
BOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with rare diseases of...
X4 Pharmaceuticals to Report Second-Quarter 2023 Financial Results and Host a Conference Call and Webcast on August 10, 2023
August 02, 2023 08:01 ET
|
X4 Pharmaceuticals
BOSTON, Aug. 02, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of...
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 30, 2023 16:05 ET
|
X4 Pharmaceuticals
BOSTON, June 30, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with rare diseases of...
X4 Pharmaceuticals Expected to Join Russell 3000® Index
June 13, 2023 08:00 ET
|
X4 Pharmaceuticals
BOSTON, June 13, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with rare diseases of...
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 02, 2023 16:05 ET
|
X4 Pharmaceuticals
BOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with rare diseases of...
X4 Pharmaceuticals Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and Duration of Infections vs. Placebo in Participants Diagnosed with WHIM Syndrome
May 16, 2023 16:01 ET
|
X4 Pharmaceuticals
~60% reduction in annualized infection rate seen in the mavorixafor arm vs. placebo (p<0.01) >75% reduction in the percentage of individuals experiencing severe infections (Grade 3 or higher)...
X4 Pharmaceuticals Announces $65 Million Private Placement Priced At-the-Market
May 16, 2023 08:30 ET
|
X4 Pharmaceuticals
BOSTON, May 16, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit people with rare diseases...
X4 Pharmaceuticals Reports First-Quarter 2023 Financial Results and Provides Corporate Update
May 04, 2023 06:05 ET
|
X4 Pharmaceuticals
Company to host webinar event on May 16th presenting new clinical data from the4WHIM Phase 3 trial; oral presentation to follow on May 21st at the 2023Clinical Immunology Society (CIS) Annual Meeting ...
X4 Pharmaceuticals to Report First-Quarter 2023 Financial Results and Host a Conference Call and Webcast on May 4, 2023
April 26, 2023 08:01 ET
|
X4 Pharmaceuticals
BOSTON, April 26, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases...